Chile was the first country in the Americas to conduct surveillance for congenital rubella syndrome (CRS) as part of screening for common causes of congenital birth defects (referred to as TORCH pathogens). The surveillance system identified 15 CRS cases in 1999 and 2 cases in 2000, and it has identified no CRS cases since 2000. CRS surveillance in Chile meets recommended surveillance standards and may serve as a model for CRS surveillance in other countries.
Rubella is a typically mild viral exanthem that presents few complications. The disease is characterized by fever and generalized rash that spontaneously resolve after a few days [1] . In 1941, the Australian ophthalmologist Norman Gregg noticed an unusual number of infants born with congenital cataracts in Sydney and other Australian cities. In almost all cases, the infant's mother reported having symptoms of rubella infection during the first trimester of pregnancy, which coincided with an extensive rubella epidemic occurring throughout Australia [2] . Gregg described the infants' clinical signs in great detail: nuclear cataracts, microphthalmia, retinopathy, incomplete response to dilation of the pupil, and temporary corneal opacity, in addition to the presence of patent ductus arteriosis, low birthweight, and irritability [2] . This combination of conditions came to be known as congenital rubella syndrome (CRS). In surviving infants, manifestations of CRS may be transitory (low birthweight and purpura) or permanent (deafness, congenital cardiopathy, and mental retardation), may require medical intervention (congenital cataracts and heart defects), and may even appear later in life (diabetes, thyroid disorders) [3] [4] [5] . The World Health Organization estimates that worldwide more than 100 000 infants are born with CRS annually, predominantly in developing countries [6] .
In 1997, the Technical Advisory Group on VaccinePreventable Diseases (TAG) of the Pan American Health Organization (PAHO) recommended the implementation of CRS surveillance in countries with rubella immunization programs [7] . The main objective of surveillance is to document the occurrence of CRS; surveillance may also identify gaps in rubella and CRS elimination strategies [8] . Because CRS surveillance depends mainly on passive reporting, evaluating completeness of CRS surveillance is challenging. In 2006, PAHO's TAG endorsed use of screening for 5 principal causes of congenital birth defects (toxoplasmosis, rubella, cytomegalovirus, herpes simplex, and syphilis or others [also referred to as TORCH pathogens]) to strengthen CRS surveillance [9] . The endorsement was based on Chile's experience integrating surveillance for CRS with screening for TORCH pathogens among infants born with congenital malformations.
Vaccination is the principal form of prevention of rubella and CRS. In 1990, Chile introduced rubella vaccination into the routine infant immunization schedule with a single dose at 12 months of age. One year later, in 1991, a second dose was added to the recommended immunization schedule at 4 years of age (changed to 6 years of age in 1993) [10] . A dramatic decline in rubella incidence was observed from 1990 to 1996, with rates reaching a nadir of 7.6 cases per 100 000 population in 1996 (Figure 1 ). During a rubella epidemic in 1997 and 1998, rubella incidence resurged to 26 and 30 cases, respectively, per 100 000, with a shift in the age distribution of cases to adolescents and young adults.
In response to increasing rubella incidence in the 1990s, the Chilean Ministry of Health conducted a national vaccination campaign against rubella in 1999. In order to improve CRS surveillance prior to the campaign, the Ministry of Health strengthened existing surveillance for TORCH pathogens. The CRS surveillance system had 3 objectives: (1) provide data to monitor the effectiveness of strategies and interventions by tracking trends over time; (2) identify population groups or geographic areas that require additional control measures to reduce disease incidence; and (3) evaluate vaccine effectiveness, duration of vaccine-conferred immunity, and other aspects related to vaccine effectiveness and safety. From 2005, active CRS surveillance was integrated with surveillance for TORCH pathogens.
Prior to 1990, the Instituto de Salud Pú blica de Chile (Chilean Institute of Public Health), the national reference center for infectious disease surveillance, received samples for laboratory confirmation of syndromes caused by TORCH pathogens. From 1993 through 1995, as part of the evaluation of suspected TORCH cases, diagnosis of rubella infection was based on a hemoagglutination inhibition assay (HIA) [11] , which required sera from both infants and mothers for testing in parallel. However, the Public Health Institute did not always receive sera from the mothers. Suspected cases of TORCH syndrome were defined as infants who presented a collection of signs and symptoms detected during the intrauterine period, during birth, or following birth, including sequelae that presented later in life (eg, interuterine growth retardation, nonimmune fetal hydrops, prematurity, low weight for gestational age, hepatomegaly, splenomegaly, purpura, jaundice, anemia, microcephalia, hydrocephalia, cerebral calcifications, chorioretinitis, pneumonitis, and musculoskeletal alterations).
In addition to HIAs, sera submitted for differential diagnosis of TORCH pathogens were tested at the Public Health Institute for the presence of antirubella-and anticytomegalovirusspecific immunoglobulin M (IgM) antibodies using commercial enzyme-linked immunosorbent assays (ELISAs): Rubenostika II IgM ELISA (bioMérieux) until 2000 and VIDAS rubella IgM ELISA (bioMérieux) and Enzygnost rubella IgM ELISA (Dade Behring-Siemens Healthcare Diagnostics) from 2001. In addition to improved sensitivity and specificity compared with HIA, paired serum samples from infants and mothers were not required when ELISA testing was performed.
As part of enhanced CRS surveillance, serum specimens were collected from infants whose mothers had been exposed to rubella or had confirmed rubella infection during pregnancy, and from infants born with signs and symptoms compatible with CRS to test for the presence of rubella-specific IgM antibodies. The suspect and compatible case definitions [10] were distributed to maternity wards and specialty departments (cardiology, neurology, and ophthalmology) of all public and private hospitals in Chile. In addition, the Chilean Ministry of Health increased laboratory capacity for rubella diagnosis at the Public Health Institute in order to monitor the effectiveness of rubella control strategies. Notification of suspected cases was mandatory. Standard case report forms were required for suspected cases, including data for the infant, mother, and mother's pregnancy. Serum samples were maintained between 4°C and 8°C and sent to the Public Health Institute as soon as possible after collection.
Beginning in 1999, samples for viral detection were collected from newborn infants with congenital abnormalities consistent with CRS who tested positive for the presence of rubella-specific IgM antibodies. As soon as results of initial serology became available, the Public Health Institute contacted the health center that had reported the case and delivered viral transport media. Samples were obtained by nasopharyngeal aspiration using a Nasogastric Feeding Tube 8 or nasopharyngeal swab. Nasopharyngeal specimens were placed in viral transport media, placed at 4°C-8°C, and sent to the Public Health Institute, where the samples were maintained at 270°C until processing for viral isolation.
Numbers of infants screened for TORCH pathogens per 10 000 live births from 1993 through 2010 are shown in Table 1 . All samples were collected from infants younger than 1 year of age, the majority from infants in the first month of life. From 1993 to 1995, 671 serum pairs from infants and mothers were received at the Chilean Public Health Institute for diagnosis of TORCH syndrome, corresponding to screening rates of 7.1-8.8 suspected cases per 10 000 live births. None of the infant samples submitted for TORCH screening during this period were positive for rubella IgM antibodies.
In 1995, 1 infant whose mother was exposed to rubella during pregnancy tested positive for rubella IgM antibodies by ELISA. The infant did not have signs or symptoms of CRS and was classified as a case of congenital rubella infection. A second case of congenital rubella infection was identified in 1996. Among 131 serum samples from infants born to mothers exposed to rubella during pregnancy, 1 serum tested positive for rubella IgM antibodies by ELISA, and initial and follow-up serum samples from the same infant demonstrated seroconversion by HIA from negative titers to a titer of 1:160.
In 1997, the Public Health Institute identified 4 rubellapositive serum specimens, 2 of which (positive by HIA in paired infant-mother sera) were from infants born to rubella-exposed mothers and 2 (positive by rubella IgM ELISA and HIA) from infants with suspected TORCH syndrome. One of the infants with suspected TORCH presented cataracts and congenital cardiopathy and was classified as a confirmed CRS case.
In 1999, 13 CRS cases were identified as a result of screening for TORCH syndrome. Rubella genotype 1E was isolated from nasopharyngeal aspirate from a 5-day-old infant with confirmed CRS. The infant was born at 32 weeks gestation, with low weight for gestational age, and was diagnosed with purpuric syndrome, congenital cardiopathy, and intrauterine malnutrition.
In September 1999, the Chilean Ministry of Health implemented active CRS surveillance. From the first quarter of 1999 through the first quarter of 2000, a total of 17 confirmed CRS cases were identified in the health regions of Atacama (Region III), Concepció n (Region IV), Metropolitan region (including Santiago), Coquimbo (Region V), and Viña del Mar-Quillota (Region VIII). In 3 of the 17 infants with confirmed CRS, congenital malformations were not observed at birth. The remaining 14 infants presented with cataracts, cardiopathy, microcephaly, purpura, and interuterine growth retardation.
Implementation of the CRS surveillance system provided data to evaluate the effectiveness of rubella control activities. From 12 August to 10 September 1999, the Chilean Ministry of Health conducted a national rubella vaccination campaign targeting females from 10 to 29 years of age. A total of 2 467 495 doses of measles-rubella vaccine were administered during the campaign, corresponding to estimated coverage of 99% of the target population. The highest estimated coverage was achieved among girls 10-14 years of age and women 25-29 years of age. The majority of regions achieved 90% or greater coverage among the target population. As a result of mass vaccination of a large NOTE. CRS, congenital rubella syndrome; IgM, immunoglobulin M; ., data not available. a TORCH is an acronym for major causes of congenital defects, and stands for toxoplasmosis, other (including syphilis), rubella, cytomegalovirus and herpes simplex virus.
b Rate per 10 000 live births.
c Congenital rubella infection is defined as presence of rubella IgM antibodies in an infant without signs or symptoms compatible with CRS.
percentage of the female population, the seasonal peak of rubella expected in the last quarter of 1999 was prevented and rubella incidence reached just 11 cases per 100 000 population in 1999, down from 31 cases per 100 000 in 1998. Targeted vaccination of females 10-29 years of age continued through 30 June 2000 to provide vaccination opportunities for those who were pregnant or had not been vaccinated during the campaign. Following this extended period, administrative coverage estimates (based on the number of doses administered) reached 100% in several regions. The national CRS surveillance system detected no cases of CRS from 2000 through 2007 (Table 1) .
The CRS surveillance system also provided evidence of the impact of mass vaccination of females on prevention of CRS cases during subsequent rubella outbreaks in Chile. In February 2005, the Chilean Ministry of Health was notified of an outbreak of rubella genotype 1C among military recruits in the city of Viña del Mar, with a total of 24 confirmed rubella cases among individuals 18-22 years of age [10] . Respiratory isolation of symptomatic individuals until 7 days after rash onset, avoidance of contact with family members, and vaccination of contacts and hospital staff contained the outbreak [10] . The Ministry of Health also conducted mass vaccination of military recruits at the facility and of the population of the Valparaíso region. The outbreak was not associated with any cases of CRS.
Further evidence for the effectiveness of the mass vaccination of females in 1999-2000 was provided during a widespread epidemic of rubella genotype 2B that began in April 2007 and resulted in more than 4000 reports of rubella from all regions of Chile except Coyhaique (Region XI), with the smallest population. Males accounted for 96% of confirmed rubella cases during the epidemic, with a median age of 23 years and peak incidence among men 21-24 years of age [10] . To interrupt rubella transmission and prevent CRS cases, the Chilean Ministry of Health decided to conduct mass vaccination of men 19-29 years of age. The vaccination campaign took place from 5 November through 14 December 2007, and it reached an estimated coverage of 92% of the target population, based on administrative data.
The CRS surveillance system identified 3 infants who tested positive for rubella IgM antibodies following the 2007 rubella epidemic; 2 were diagnosed with CRS but attempts to detect rubella virus in nasopharyngeal swabs obtained from 1 of the infants were unsuccessful. One of the positive reactions occurred in an infant diagnosed with congenital syphilis and may have resulted from cross-reactivity of the rubella immunoassay. No confirmed rubella cases have been identified in Chile since 2008.
To maintain sensitivity of CRS surveillance systems in the postelimination era, PAHO recommends a minimum annual notification rate of 1 suspect CRS case per 10 000 live-born infants [12] . Integration of the CRS surveillance system in Chile with passive surveillance for TORCH syndrome resulted in greater sensitivity of CRS surveillance in Chile and surpassed the recommended minimum notification rate. The majority of congenital rubella infections identified from 1993 through 2000 were detected through screening for TORCH pathogens.
The major limitation of the CRS surveillance system in Chile is that the small number of CRS cases identified provides few data for evaluation of interventions and identification of at-risk populations. In addition, data are not available on the proportion of all children meeting the suspect case definition for TORCH syndrome who have sera sent to the national reference laboratory for testing. Infections with TORCH pathogens among Chilean infants are likely underestimated, considering that diagnostic testing is requested for approximately 0.1% of 240 000 live-born infants annually. In contrast, 1 hospital-based study in Rancagua, Chile, reported a rate of 41 infants with congenital malformations per 1000 live births, or 4.1% [13] . At 8 Chilean hospitals that participated in the Latin-American Collaborative Study of Congenital Malformations (ECLAMC), the number of infants born with congenital malformations was much greater than the number of samples submitted to the national reference laboratory for TORCH screening [14] . In addition to integration of CRS surveillance with that for TORCH syndrome, an index of suspicion of CRS needs to be maintained to avoid missing imported cases.
